Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-04-19
2011-04-19
Goddard, Laura B (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C536S023100, C536S024310, C536S024330
Reexamination Certificate
active
07927806
ABSTRACT:
This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
REFERENCES:
patent: 4581333 (1986-04-01), Kourilsky et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4786600 (1988-11-01), Kramer et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 4851331 (1989-07-01), Vary
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5002867 (1991-03-01), Macevicz
patent: 5068176 (1991-11-01), Vijg et al.
patent: 5082670 (1992-01-01), Gage et al.
patent: 5112736 (1992-05-01), Caldwell et al.
patent: 5118801 (1992-06-01), Lizardi
patent: 5149625 (1992-09-01), Church et al.
patent: 5174986 (1992-12-01), Berns et al.
patent: 5175383 (1992-12-01), Leder et al.
patent: 5183949 (1993-02-01), Kindt et al.
patent: 5202231 (1993-04-01), Drmanac et al.
patent: 5219989 (1993-06-01), Sonenberg et al.
patent: 5283174 (1994-02-01), Arnold, Jr. et al.
patent: 5312728 (1994-05-01), Lizardi et al.
patent: 5399491 (1995-03-01), Kacian et al.
patent: 5422252 (1995-06-01), Walker et al.
patent: 5466590 (1995-11-01), Sariaslani et al.
patent: 5503980 (1996-04-01), Cantor
patent: 5547842 (1996-08-01), Hogan et al.
patent: 5554516 (1996-09-01), Kaclan et al.
patent: 5585481 (1996-12-01), Arnold, Jr. et al.
patent: 5593974 (1997-01-01), Rosenberg et al.
patent: 5639604 (1997-06-01), Arnold, Jr. et al.
patent: 5656207 (1997-08-01), Woodhead et al.
patent: 5658737 (1997-08-01), Nelson et al.
patent: 5674682 (1997-10-01), Croce et al.
patent: 5773705 (1998-06-01), Vierstra et al.
patent: 5837832 (1998-11-01), Chee et al.
patent: 5861242 (1999-01-01), Chee et al.
patent: 5925517 (1999-07-01), Tyagi et al.
patent: 5939258 (1999-08-01), Croce et al.
patent: 6037130 (2000-03-01), Tyagi et al.
patent: 6087133 (2000-07-01), Dattagupta et al.
patent: 6110678 (2000-08-01), Weisburg et al.
patent: 6261562 (2001-07-01), Xu et al.
patent: 6262245 (2001-07-01), Xu et al.
patent: 6280952 (2001-08-01), Weisburg et al.
patent: 6287820 (2001-09-01), Umansky et al.
patent: 6383739 (2002-05-01), Kurth et al.
patent: 6395278 (2002-05-01), Xu et al.
patent: 6465611 (2002-10-01), Xu et al.
patent: 6479263 (2002-11-01), Slawin et al.
patent: 6528260 (2003-03-01), Blumenfeld et al.
patent: 6534273 (2003-03-01), Weisburg et al.
patent: 6551778 (2003-04-01), Harvey et al.
patent: 6800746 (2004-10-01), Xu et al.
patent: 6897024 (2005-05-01), Bussemakers et al.
patent: 7008765 (2006-03-01), Bussemakers et al.
patent: 7138235 (2006-11-01), Bussemakers et al.
patent: 7368545 (2008-05-01), Busse et al.
patent: 7632643 (2009-12-01), Bussemakers et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2002/0035244 (2002-03-01), Cohen et al.
patent: 2002/0168638 (2002-11-01), Schlegel et al.
patent: 2003/0165850 (2003-09-01), Bussemakers et al.
patent: 2005/0158792 (2005-07-01), Bussemakers et al.
patent: 2005/0164223 (2005-07-01), Schalken et al.
patent: 2005/0282170 (2005-12-01), Fradet et al.
patent: 2006/0099658 (2006-05-01), Bussemakers et al.
patent: 2010/0021884 (2010-01-01), Hessels et al.
patent: 0125023 (1984-11-01), None
patent: 0160228 (1985-11-01), None
patent: 0171496 (1986-02-01), None
patent: 0173494 (1986-05-01), None
patent: 0184187 (1986-11-01), None
patent: 0256932 (1988-02-01), None
patent: 0520794 (1992-12-01), None
patent: 0320308 (1993-03-01), None
patent: 0747706 (1996-12-01), None
patent: 1295125 (2006-05-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 87/02671 (1986-10-01), None
patent: WO 90/00944 (1990-02-01), None
patent: WO 91/19008 (1991-12-01), None
patent: WO 93/03743 (1993-04-01), None
patent: WO 93/08845 (1993-05-01), None
patent: WO 93/13121 (1993-07-01), None
patent: WO 94/09820 (1994-05-01), None
patent: WO 94/15646 (1994-07-01), None
patent: WO 95/28498 (1995-10-01), None
patent: WO 95/32305 (1995-11-01), None
patent: WO 96/11266 (1996-04-01), None
patent: WO 96/14875 (1996-05-01), None
patent: WO 96/32966 (1996-10-01), None
patent: WO 98/02582 (1998-01-01), None
patent: WO 98/45420 (1998-10-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO 00/50899 (2000-08-01), None
patent: WO 00/58470 (2000-10-01), None
patent: WO 01/23550 (2001-04-01), None
patent: WO 01/25272 (2001-04-01), None
patent: WO 01/25273 (2001-04-01), None
patent: WO 01/34802 (2001-05-01), None
patent: WO 01/44507 (2001-06-01), None
patent: WO 01/51633 (2001-07-01), None
patent: PCT/CA00/01154 (2001-08-01), None
patent: WO 01/60860 (2001-08-01), None
patent: WO 01/73032 (2001-10-01), None
patent: WO 02/24718 (2002-03-01), None
patent: WO 02/30268 (2002-04-01), None
patent: PCT/CA00/01154 (2002-08-01), None
patent: WO 2004/070056 (2004-08-01), None
Watala et al., “Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients”, Thrombosis Journal, 30;1(1):7 (2003).
Wei, C., et al., Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: Implications for tolerance and immunotherapy, Proc. Natl. Acad. Sci. USA 94:6369-6374, The National Academy of Sciences of the USA (1997).
Weiss, R., “Hot Prospect for New Gene Amplifier,” Science 254:1292-1293, American Association for the Advancement of Science (1991).
Xu et al., “Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer”. J Urol. 163:972-9 (2000).
Yelin et al., “Widespread occurrence of antisense transcription in the human 1, genome,” Nat. Biotechnol. 21 :379-386, Nature Publishing Group (Apr. 2003).
Ylikoski et al., “Dual-label detection of amplified products in quantitative RT-PCR assay using lanthanide-labeled probes”. Biotechniques. 30:832-6, 838, 840 (2001).
Ylikoski et al., “Quantitative reverse transcription-PCR assay with an internal standard for the detection of prostate-specific antigen mRNA”. Clin Chem. 45:1397-407 (1999).
Altschul, S.F., et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucl. Acids Res. 25:3389-3402, Oxford University Press (1997).
Armbruster et al., “Enzyme immunoassay, kinetic microparticle immunoassay, radioimmunoassay, and fluorescence polarization immunoassay compared for drugs-of-abuse screening”, Clin Chem. 39(10):2137-46 (1993).
Arnold, Jr., L.J., et al., “Assay Formats Involving Acridinium-Ester-Labe/ed DNA Probes,” Clin. Chem. 35:1588-1594, American Association for Clinical Chemistry (1989).
Auffray C, Rougeon F. “Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA”. Eur J Biochem 1980;107:303-14.
Barbu V, Dautry F. “Northern blot normalization with a 28S rRNA oligonucleotide probe”. Nucleic Acids Res 1989;17:7115.
Beduschi MC, Oesterling JE. “Percent free prostate-specific antigen: the next frontier in prostate-specific antigen testing”. Urology 51:98-109 (1998).
Bernard PS, Wittwer CT. “Real-time PCR technology for cancer diagnostics”. Clin Chem. 48:1178-85 (2002).
Black, D.L., “Mechanisms of Alternative Pre-Messenger RNA Splicing,” Annu. Rev. Biochem. 72:291-336 (Feb. 2003).
Boom, R., et al., “Rapid and Simple Method for Purification of Nucleic Acids,” J. Clin, Microbiol. 28:495-503, American Society for Microbiology (1990).
Boulikas, T., “Gene Therapy of Prostate Cancer: p53, Suicidal Genes, and Other Targets,” Anticancer Res. 17:1471-1
Busse Ursula
Chypre Camille
Fradet Yves
Diagnocure Inc.
Goddard Laura B
Goudreau Gage Dubuc
Goyer Charles
LandOfFree
Distinguishing PCA3 messenger RNA species in benign and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Distinguishing PCA3 messenger RNA species in benign and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Distinguishing PCA3 messenger RNA species in benign and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2729498